<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> were treated with daily subcutaneous injections of interferon alpha 2a, at the initial dose of 3 x 10(6) U/m2 </plain></SENT>
<SENT sid="1" pm="."><plain>Hemogram, chemistry profile, natural killer (NK) cell activity and lymphokine-activated killer (LAK) cell cytotoxicity were monitored serially </plain></SENT>
<SENT sid="2" pm="."><plain>Bone marrow with cytogenetic analysis was done before therapy and every three months afterwards </plain></SENT>
<SENT sid="3" pm="."><plain>Normalization to the complete blood count, and wherever applicable, decrease in blast count of 5% or less were defined as a complete response </plain></SENT>
<SENT sid="4" pm="."><plain>Improvement in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level to 12 g/dl, neutrophil count to 1000/mm3 and platelets to 100,000/mm3 was considered a partial response </plain></SENT>
<SENT sid="5" pm="."><plain>The median age was 71 (range 59-83) years and 16 of the patients were males </plain></SENT>
<SENT sid="6" pm="."><plain>Two patients withdrew from the treatment in the first week and were considered ineligible </plain></SENT>
<SENT sid="7" pm="."><plain>Among the other 18, two had <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>, two <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo>, four <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, eight <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts, and two <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Twelve patients were treated for six months, the other six were taken off the treatment after six to eight weeks because of disease progression </plain></SENT>
<SENT sid="9" pm="."><plain>Only one patient with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> had a partial response for two months </plain></SENT>
<SENT sid="10" pm="."><plain>NK cell activity remained unchanged before (18.3 +/- 4.6 lytic units) and during interferon therapy (19.6 +/- 5.3 lytic units) </plain></SENT>
<SENT sid="11" pm="."><plain>LAK cytotoxicity was not detected in any patient before therapy and was seen in only one patient (not the responder) during therapy (5.7 lytic units) </plain></SENT>
<SENT sid="12" pm="."><plain>The toxicity of the interferon therapy was substantial </plain></SENT>
<SENT sid="13" pm="."><plain>Seventeen patients required a dose reduction and fifteen lost greater than 10% of body weight </plain></SENT>
<SENT sid="14" pm="."><plain>Eleven patients (61%) developed <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> requiring antibiotic therapy, and eight (44%) required hospitalization </plain></SENT>
<SENT sid="15" pm="."><plain>Seven patients developed neurologic toxicity </plain></SENT>
<SENT sid="16" pm="."><plain>Interferon alpha 2a is an ineffective but toxic therapy in these elderly patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
</text></document>